Magellan Health (MGLN) Tops Q3 EPS Views; Boosts FY14 EPS Outlook

Magellan Health (NASDAQ: MGLN) reported Q3 adjusted EPS of $1.30, $0.83 better than the analyst estimate of $0.47. Revenue for the quarter came in at $823.2 million versus the consensus estimate of $930.1 million.

Magellan Health sees FY2014 EPS of $3.21-$3.72, versus the consensus of $2.16. Magellan Health sees FY2014 revenue of $3.6-3.8 billion, versus the consensus of $3.79 billion.

For earnings history and earnings-related data on Magellan Health (MGLN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Movano (MOVE) Misses Q2 EPS by 195c